BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hammerstad SS, Grock SF, Lee HJ, Hasham A, Sundaram N, Tomer Y. Diabetes and Hepatitis C: A Two-Way Association. Front Endocrinol (Lausanne). 2015;6:134. [PMID: 26441826 DOI: 10.3389/fendo.2015.00134] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 7.8] [Reference Citation Analysis]
Number Citing Articles
1 Li J, Zhang T, Gordon SC, Rupp LB, Trudeau S, Holmberg SD, Moorman AC, Spradling PR, Teshale EH, Boscarino JA, Schmidt MA, Daida YG, Lu M; CHeCS Investigators. Impact of sustained virologic response on risk of type 2 diabetes among hepatitis C patients in the United States. J Viral Hepat. 2018;25:952-958. [PMID: 29478263 DOI: 10.1111/jvh.12887] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 6.3] [Reference Citation Analysis]
2 Rajkumar P, Dwivedi AK, Dodoo CA, Shokar NK, Salinas J, Lakshmanaswamy R. The association between metabolic syndrome and Hepatitis C virus infection in the United States. Cancer Causes Control 2020;31:569-81. [PMID: 32300943 DOI: 10.1007/s10552-020-01300-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Kalmykova ZA, Kononenko IV, Mayorov AY. [Diabetes mellitus and chronic liver diseases. Part 1: general mechanisms of etiology and pathogenesis]. Ter Arkh 2019;91:106-11. [PMID: 32598639 DOI: 10.26442/00403660.2019.10.000165] [Reference Citation Analysis]
4 Smolders EJ, Colbers A, de Kanter CTMM, Velthoven-Graafland K, Wolberink LT, van Ewijk-Beneken Kolmer N, Drenth JPH, Aarnoutse RE, Tack CJ, Burger DM. Metformin and daclatasvir: absence of a pharmacokinetic-pharmacodynamic drug interaction in healthy volunteers. Br J Clin Pharmacol 2017;83:2225-34. [PMID: 28474741 DOI: 10.1111/bcp.13323] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
5 Wong AH, Sie J, Chen A, Gunawan B, Chung J, Rashid N. Glycemic Control after Initiating Direct-Acting Antiviral Agents in Patients with Hepatitis C Virus and Type 2 Diabetes Mellitus Using the United States Integrated Healthcare System. J Res Pharm Pract 2020;9:16-23. [PMID: 32489956 DOI: 10.4103/jrpp.JRPP_19_110] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Abdel Monem MS, Farid SF, Abbassi MM, Youssry I, Andraues NG, Hassany M, Selim YMM, El-Sayed MH. The potential hepatoprotective effect of metformin in hepatitis C virus-infected adolescent patients with beta thalassemia major: Randomised clinical trial. Int J Clin Pract 2021;75:e14104. [PMID: 33617679 DOI: 10.1111/ijcp.14104] [Reference Citation Analysis]
7 Flores YN, Zhang ZF, Bastani R, Leng M, Crespi CM, Ramírez-Palacios P, Stevens H, Salmerón J. Risk factors for liver disease among adults of Mexican descent in the United States and Mexico. World J Gastroenterol 2018; 24(37): 4281-4290 [PMID: 30310261 DOI: 10.3748/wjg.v24.i37.4281] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
8 Cacciola I, Russo G, Filomia R, Pitrone C, Caccamo G, Giandalia A, Alibrandi A, Stella Franzè M, Porcari S, Maimone S, Saitta C, Squadrito G, Raimondo G. Over time evaluation of glycaemic control in direct-acting antiviral-treated hepatitis C virus/diabetic individuals with chronic hepatitis or with cirrhosis. Liver Int 2021;41:2059-67. [PMID: 33894103 DOI: 10.1111/liv.14905] [Reference Citation Analysis]
9 Chávez-Reyes J, Escárcega-González CE, Chavira-Suárez E, León-Buitimea A, Vázquez-León P, Morones-Ramírez JR, Villalón CM, Quintanar-Stephano A, Marichal-Cancino BA. Susceptibility for Some Infectious Diseases in Patients With Diabetes: The Key Role of Glycemia. Front Public Health 2021;9:559595. [PMID: 33665182 DOI: 10.3389/fpubh.2021.559595] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
10 Drazilova S, Janicko M, Skladany L, Kristian P, Oltman M, Szantova M, Krkoska D, Mazuchova E, Piesecka L, Vahalova V, Rac M, Schreter I, Virag L, Koller T, Liptakova A, Ondrasova M, Jarcuska P. Glucose Metabolism Changes in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals. Can J Gastroenterol Hepatol 2018;2018:6095097. [PMID: 30402450 DOI: 10.1155/2018/6095097] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
11 Gitto S, Cursaro C, Bartoli A, Margotti M, Andreone P. Hepatitis C: clinical management and debated issues. Minerva Med 2021;112:228-37. [PMID: 33319975 DOI: 10.23736/S0026-4806.20.07208-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Hammerstad SS, Blackard JT, Lombardi A, Owen RP, Concepcion E, Yi Z, Zhang W, Tomer Y. Hepatitis C Virus Infection of Human Thyrocytes: Metabolic, Hormonal, and Immunological Implications. J Clin Endocrinol Metab 2020;105:dgz241. [PMID: 31784757 DOI: 10.1210/clinem/dgz241] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Polo ML, Laufer N. Extrahepatic manifestations of HCV: the role of direct acting antivirals. Expert Rev Anti Infect Ther. 2017;15:737-746. [PMID: 28696154 DOI: 10.1080/14787210.2017.1354697] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
14 Dou XG, Bai H. Diagnosis and Treatment of Chronic Hepatitis C with Concomitant Extrahepatic Manifestations Deserves a Closer Look. J Transl Int Med 2017;5:1-3. [PMID: 28680832 DOI: 10.1515/jtim-2017-0009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Liu Y, Ye S, Xiao X, Zhou T, Yang S, Wang G, Sun C, Zhang B, Wang G. Association of diabetes mellitus with hepatitis B and hepatitis C virus infection: evidence from an epidemiological study. Infect Drug Resist 2019;12:2875-83. [PMID: 31686868 DOI: 10.2147/IDR.S218536] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
16 Zhang M, O'Keefe D, Craig J, Samley K, Bunreth V, Jolivet P, Balkan S, Marquardt T, Dousset JP, Le Paih M. Decentralised hepatitis C testing and treatment in rural Cambodia: evaluation of a simplified service model integrated in an existing public health system. Lancet Gastroenterol Hepatol 2021;6:371-80. [PMID: 33743883 DOI: 10.1016/S2468-1253(21)00012-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
17 Rafique S, Zahid S, Ali A, Tariq M, Saeed M, Iqbal Sahibzada K, Ali Shahid A, Idrees M. Genome-wide methylation profiling of HCV pathogenesis to develop diabetes and diabetic complications. J Viral Hepat 2021;28:245-59. [PMID: 33051931 DOI: 10.1111/jvh.13417] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Driedger M, Galanakis C, Doyle MA, Cooper CL. Direct-acting antiviral hepatitis C virus treatment perturbation of the metabolic milieu. Eur J Gastroenterol Hepatol 2019;31:260-6. [PMID: 30379706 DOI: 10.1097/MEG.0000000000001292] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 De Weggheleire A, An S, De Baetselier I, Soeung P, Keath H, So V, Ros S, Teav S, Smekens B, Buyze J, Florence E, van Griensven J, Thai S, Francque S, Lynen L. A cross-sectional study of hepatitis C among people living with HIV in Cambodia: Prevalence, risk factors, and potential for targeted screening. PLoS One 2017;12:e0183530. [PMID: 28832660 DOI: 10.1371/journal.pone.0183530] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
20 Santos M, Protopopescu C, Delarocque-Astagneau E, Bourlière M, Petrov-Sanchez V, Di Beo V, Larrey D, Baudoin M, Dorival C, Bureau M, Fontaine H, Carrat F, Marcellin F, Pol S, Carrieri P; ANRS CO22 HEPATHER study group. Late presentation for HCV care: Time to target people with diabetes and/or hazardous alcohol use (ANRS CO22 HEPATHER cohort). Liver Int 2021. [PMID: 34520614 DOI: 10.1111/liv.15056] [Reference Citation Analysis]
21 Cao LH, Lu FM, Lu XJ, Zhu LY. Study on the relationship between insulin growth factor 1 and liver fibrosis in patients with chronic hepatitis C with type 2 diabetes mellitus. J Cell Biochem 2018;119:9513-8. [PMID: 30105830 DOI: 10.1002/jcb.27267] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
22 Kalmykova ZA, Kononenko IV, Mayorov AY. [Diabetes mellitus and chronic liver diseases. Literature review (part 2): treatment features]. Ter Arkh 2019;91:115-21. [PMID: 32598598 DOI: 10.26442/00403660.2019.12.000166] [Reference Citation Analysis]
23 Silva TE, Ronsoni MF, Schiavon LL. Challenges in diagnosing and monitoring diabetes in patients with chronic liver diseases. Diabetes Metab Syndr. 2018;12:431-440. [PMID: 29279271 DOI: 10.1016/j.dsx.2017.12.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
24 Gallagher EJ, Neel BA, Antoniou IM, Yakar S, Leroith D. The Increased Risk of Cancer in Obesity and Type 2 Diabetes: Potential Mechanisms. In: Poretsky L, editor. Principles of Diabetes Mellitus. Cham: Springer International Publishing; 2017. pp. 731-53. [DOI: 10.1007/978-3-319-18741-9_36] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Drazilova S, Gazda J, Janicko M, Jarcuska P. Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy. Can J Gastroenterol Hepatol 2018;2018:6150861. [PMID: 30186821 DOI: 10.1155/2018/6150861] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
26 Zeng H, Li L, Hou Z, Zhang Y, Tang Z, Liu S. Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges. Int J Med Sci. 2020;17:892-902. [PMID: 32308542 DOI: 10.7150/ijms.43079] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
27 Aas CF, Vold JH, Skurtveit S, Odsbu I, Chalabianloo F, Lim AG, Johansson KA, Fadnes LT. Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017. Subst Abuse Treat Prev Policy 2020;15:44. [PMID: 32605625 DOI: 10.1186/s13011-020-00286-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
28 Barré T, Nishimwe ML, Protopopescu C, Marcellin F, Carrat F, Dorival C, Delarocque‐astagneau E, Larrey D, Bourlière M, Petrov‐sanchez V, Simony M, Pol S, Fontaine H, Carrieri P; the ANRS/AFEF Hepather study group. Cannabis use is associated with a lower risk of diabetes in chronic hepatitis C‐infected patients (ANRS CO22 Hepather cohort). J Viral Hepat 2020;27:1473-83. [DOI: 10.1111/jvh.13380] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
29 Santos AH Jr, Casey MJ, Xuerong W, Womer KL. Association of Baseline Viral Serology and Sirolimus Regimens With Kidney Transplant Outcomes: A 14-Year Registry-Based Cohort Study in the United States. Transplantation 2017;101:377-86. [PMID: 28121742 DOI: 10.1097/TP.0000000000001520] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 2.8] [Reference Citation Analysis]
30 Pashun RA, Shen NT, Jesudian A. Markedly Improved Glycemic Control in Poorly Controlled Type 2 Diabetes following Direct Acting Antiviral Treatment of Genotype 1 Hepatitis C. Case Reports Hepatol 2016;2016:7807921. [PMID: 27293923 DOI: 10.1155/2016/7807921] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
31 Yair-Sabag S, Nussinson E, Ben-Assuli O, Shibli F, Shahbari A, Zelber-Sagi S. Retrospective study of the associations between hepatitis C virus infection and metabolic factors. World J Hepatol 2016; 8(30): 1269-1278 [PMID: 27843537 DOI: 10.4254/wjh.v8.i30.1269] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
32 Wong T, Bloom RD. Management and treatment of the HCV-infected kidney transplant patient. Semin Dial 2019;32:169-78. [PMID: 30536995 DOI: 10.1111/sdi.12766] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
33 Gastaldi G, Goossens N, Clément S, Negro F. Current level of evidence on causal association between hepatitis C virus and type 2 diabetes: A review. J Adv Res 2017;8:149-59. [PMID: 28149650 DOI: 10.1016/j.jare.2016.11.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
34 Ridziauskas M, Zablockienė B, Jančorienė L, Samuilis A, Zablockis R, Jackevičiūtė A. Assessment of Liver Stiffness Regression and Hepatocellular Carcinoma Risk in Chronic Hepatitis C Patients after Treatment with Direct-Acting Antiviral Drugs. Medicina (Kaunas) 2021;57:210. [PMID: 33652777 DOI: 10.3390/medicina57030210] [Reference Citation Analysis]
35 Yeboah-Korang A, Beig MI, Khan MQ, Goldstein JL, Macapinlac DM, Maurer D, Sonnenberg A, Fimmel CJ. Hepatitis C Screening in Commercially Insured U.S. Birth-cohort Patients: Factors Associated with Testing and Effect of an EMR-based Screening Alert. J Transl Int Med 2018;6:82-9. [PMID: 29984203 DOI: 10.2478/jtim-2018-0012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
36 Abdelkader RY, Abdelrazek MA, Attallah A, Farid K, El-Far M. High blood glucose levels are associated with fibrosis/cirrhosis progression in chronic hepatitis C. J Immunoassay Immunochem 2021;:1-12. [PMID: 33886414 DOI: 10.1080/15321819.2021.1911813] [Reference Citation Analysis]
37 Saad Y, Awad A, Alakel W, Doss W, Awad T, Mabrouk M. Data mining of routine laboratory tests can predict liver disease progression in Egyptian diabetic patients with hepatitis C virus (G4) infection: a cohort study of 71 806 patients. Eur J Gastroenterol Hepatol 2018;30:201-6. [PMID: 29099423 DOI: 10.1097/MEG.0000000000001008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
38 Esposito S, Mariotti Zani E, Torelli L, Scavone S, Petraroli M, Patianna V, Predieri B, Iughetti L, Principi N. Childhood Vaccinations and Type 1 Diabetes. Front Immunol 2021;12:667889. [PMID: 34512622 DOI: 10.3389/fimmu.2021.667889] [Reference Citation Analysis]
39 Wainwright P, Scorletti E, Byrne CD. Type 2 Diabetes and Hepatocellular Carcinoma: Risk Factors and Pathogenesis. Curr Diab Rep 2017;17. [DOI: 10.1007/s11892-017-0851-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
40 Narne P. Impaired insulin exocytosis in chronic hepatitis C infection: contributory role of p38δ MAPK-protein kinase D-golgi complex axis. Clin Sci (Lond) 2020;134:1449-56. [PMID: 32556178 DOI: 10.1042/CS20200686] [Reference Citation Analysis]
41 Cheudjeu A. Antiviral strategies should focus on stimulating the biosynthesis of heparan sulfates, not their inhibition. Life Sci 2021;277:119508. [PMID: 33865880 DOI: 10.1016/j.lfs.2021.119508] [Reference Citation Analysis]
42 Sangineto M, Luglio CV, Mastrofilippo T, Zingaro MT, Berardi E, Antonica G, Sabbà C, Napoli N. Analysis of hepatic stiffness after viral eradication in a population with chronic hepatitis C treated with DAAs. Med Clin (Barc) 2021;156:317-23. [PMID: 32788043 DOI: 10.1016/j.medcli.2020.04.050] [Reference Citation Analysis]
43 Blackard JT, Kong L, Lombardi A, Homann D, Hammerstad SS, Tomer Y. A preliminary analysis of hepatitis C virus in pancreatic islet cells. Virol J 2017;14:237. [PMID: 29258547 DOI: 10.1186/s12985-017-0905-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
44 Lanini S, Scognamiglio P, Pisapia R, Minosse C, Agresta A, Ippolito G. Recovery of metabolic impairment in patients who cleared chronic hepatitis C infection after direct-acting antiviral therapy. Int J Antimicrob Agents 2019;53:559-63. [PMID: 30550818 DOI: 10.1016/j.ijantimicag.2018.11.024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
45 De Weggheleire A, Buyze J, An S, Thai S, van Griensven J, Francque S, Lynen L. Development of a risk score to guide targeted hepatitis C testing among human immunodeficiency virus patients in Cambodia. World J Hepatol 2021; 13(9): 1167-1180 [PMID: 34630883 DOI: 10.4254/wjh.v13.i9.1167] [Reference Citation Analysis]
46 Zhao Y, Xing H. A Different Perspective for Management of Diabetes Mellitus: Controlling Viral Liver Diseases. J Diabetes Res 2017;2017:5625371. [PMID: 28352640 DOI: 10.1155/2017/5625371] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
47 Zied HY, Abo Alnasr NM, El-Bendary AS, Abd-Elsalam S, Hagag RY. Effect of treatment with direct antiviral agents (DAAs) on glycemic control in patients with type 2 diabetes mellitus & hepatitis C virus genotype 4. Diabetes Metab Syndr 2020;14:679-82. [PMID: 32438332 DOI: 10.1016/j.dsx.2020.05.024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]